Carna Biosciences, Inc.
4572 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 神戸市中央区港島南町一丁目５番５号
- Website:
- https://www.carnabio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Carna Biosciences, Inc. is a Japanese biotechnology company focused on drug discovery and development, specializing in the fields of protein kinases and cellular signaling pathways. The company is renowned for its innovative solutions in biomarker discovery and assay development, serving pharmaceutical and biotechnology companies in their quest for novel therapeutics. Carna's proprietary technology platforms enable high-throughput screening and in-depth characterization of kinase activities, facilitating the identification of potential drug candidates. With a commitment to advancing precision medicine, Carna Biosciences plays a vital role in enhancing the efficiency of drug development processes while contributing to breakthroughs in cancer and other diseases.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-11 08:47 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 393.6 KB | |
| 2025-07-11 08:46 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 393.6 KB | |
| 2025-07-11 08:45 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 392.8 KB | |
| 2025-03-28 02:41 |
Inside Information Statement
臨時報告書
|
Japanese | 28.5 KB | |
| 2025-03-26 02:11 |
Internal Control over Financial Reporting
内部統制報告書－第22期(2024/01/01－2024/12/31)
|
Japanese | 24.5 KB | |
| 2025-03-26 02:10 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2025-03-26 02:08 |
Annual Report
有価証券報告書－第22期(2024/01/01－2024/12/31)
|
Japanese | 1.3 MB | |
| 2024-09-25 08:39 |
Inside Information Statement
臨時報告書
|
Japanese | 122.5 KB | |
| 2024-08-08 02:51 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-08-08 02:50 |
Interim Report
半期報告書－第22期(2024/01/01－2024/12/31)
|
Japanese | 213.7 KB | |
| 2024-05-15 09:51 |
Inside Information Statement
臨時報告書
|
Japanese | 114.0 KB | |
| 2024-05-13 02:38 |
Regulatory News Service
確認書
|
Japanese | 8.7 KB | |
| 2024-05-13 02:37 |
Quarterly Report
四半期報告書－第22期第1四半期(2024/01/01－2024/03/31)
|
Japanese | 173.9 KB | |
| 2024-03-28 08:47 |
Inside Information Statement
臨時報告書
|
Japanese | 30.1 KB | |
| 2024-03-27 02:59 |
Internal Control over Financial Reporting
内部統制報告書－第21期(2023/01/01－2023/12/31)
|
Japanese | 24.5 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ABIVAX | France | ABVX | |
|
Addex Therapeutics Ltd | Switzerland | ADXN | |
|
AegirBio AB | Sweden | AEGIR | |
|
AGRONOMICS LIMITED | Isle of Man | ANIC | |
|
AIREA PLC | United Kingdom | AIEA | |
|
Alkaloid AD | North Macedonia | ALK | |
| Alma Yesodot Ltd. | Israel | KVSR | ||
|
Amphastar Pharmaceuticals Inc. | United States of America | AMPH | |
| Ananda Pharma Plc | United Kingdom | N/A | ||
|
AnGes, Inc. | Japan | 4563 |